These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28822777)

  • 61. Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
    Game F
    Nephron Clin Pract; 2014; 126(1):14-8. PubMed ID: 24434725
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
    León Jiménez D; Cherney DZI; Bjornstad P; Castilla-Guerra L; Miramontes González JP
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1406-F1415. PubMed ID: 30066584
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.
    Fitchett DH; Udell JA; Inzucchi SE
    Eur J Heart Fail; 2017 Jan; 19(1):43-53. PubMed ID: 27653447
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.
    Zhao Y; Yang L; Zhou Z
    J Diabetes; 2014 Jan; 6(1):21-9. PubMed ID: 23683065
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents.
    Gnudi L; Karalliedde J
    Nephrol Dial Transplant; 2016 Jul; 31(7):1036-43. PubMed ID: 25858586
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent advances in glucose-lowering treatment to reduce diabetic kidney disease.
    Hanssen NM; Russell N; Cooper ME
    Expert Opin Pharmacother; 2015 Jun; 16(9):1325-33. PubMed ID: 25912195
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
    Goldenberg RM; Ahooja V; Clemens KK; Gilbert JD; Poddar M; Verma S
    Can J Diabetes; 2021 Apr; 45(3):291-302. PubMed ID: 33189580
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; Stompór T
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
    Wang YJ; Hao CM
    Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
    [TBL] [Abstract][Full Text] [Related]  

  • 70. More CREDENCE for SGLT2 Inhibition.
    Verma S; Bhatt DL
    Circulation; 2019 Oct; 140(18):1448-1450. PubMed ID: 31181959
    [No Abstract]   [Full Text] [Related]  

  • 71. [Type 2 diabetes mellitus: new treatments].
    Ascaso JF
    Med Clin (Barc); 2014 Aug; 143(3):117-23. PubMed ID: 23937815
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
    Block TJ; Batu D; Cooper ME
    Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.
    Kuang Z; Hou N; Kan C; Han F; Qiu H; Sun X
    Int Urol Nephrol; 2023 Mar; 55(3):617-629. PubMed ID: 36036316
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 75. Cardiorenal Protection in Diabetic Kidney Disease.
    Lee JF; Berzan E; Sridhar VS; Odutayo A; Cherney DZI
    Endocrinol Metab (Seoul); 2021 Apr; 36(2):256-269. PubMed ID: 33873265
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
    Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
    Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effects of glucose-lowering therapies on diabetic kidney disease.
    Agrawal V; Giri C; Solomon RJ
    Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
    Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
    Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Management of type 2 diabetes in chronic kidney disease.
    Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD
    BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158
    [TBL] [Abstract][Full Text] [Related]  

  • 80. GLP-1 Receptor Agonists and Kidney Protection.
    Greco EV; Russo G; Giandalia A; Viazzi F; Pontremoli R; De Cosmo S
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.